US 2013/0171243 A1Published application

Octreotide-modified nanomedicine for cancer treatment or cancer palliative care

AssigneeNanosion Co., Ltd.

InventorsYuko Iwase, Yoshie Maitani

Life of this patent

Estimating the term…

Abstract

The present invention relates to a medical composition for treatment, palliative care or prevention of cancer, such as medullary thyroid carcinoma. Specifically, the invention relates to a medical composition for treatment, palliative care or prevention of medullary thyroid carcinoma, which comprises liposomes modified with octreotide.

Claims7

Dependent claims

A medical composition for treatment, palliative care or prevention of cancer, which comprises liposomes modified with octreotide.

Dependencies are inferred from the claim text.

Facts

Application: 13/823,821Filed 23 Feb 2011
Priority: JP 2010-20874417 Sep 2010
Published: 4 Jul 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids
A61K 9/1271
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant: non-conventional liposomes,…
A61K 31/4745
Ortho- or peri-condensed with heterocyclic ring systems: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61P 35/00
Antineoplastic agents

Family

US 9,289,463 B2Related patent
US 2013/0171243 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results